Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Healthy Adults (18-80 Years Old) Finished 3 Doses Inactivated COVID-19 Vaccine: a Randomised, Double-blind, Parallel Controlled, Clinic Trial

NCT05373030 is registered in ClinicalTrials.gov with Zhejiang Provincial Center for Disease Control and Prevention as lead sponsor.

NCT NCT05373030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05373030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Healthy Adults (18-80 Years Old) Finished 3 Doses Inactivated COVID-19 Vaccine: a Randomised, Double-blind, Parallel Controlled, Clinic Trial
Lead sponsor
Zhejiang Provincial Center for Disease Control and Prevention
Phase
Phase 4
Overall status
Unknown status
Start date
May 14, 2022
Completion date
June 30, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine using for sequential immunization